Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Brief Intervention for OCD Fears

ID
Name
7293 (OCD)
Description
The study will test the efficacy of propranolol or placebo, administered after reactivation of a previously acquired obsessive-compulsive disorder (OCD) fear, in reducing fear and avoidance in OCD.
Trial arms
Trial start
2016-06-01
Estimated PCD
2023-04-01
Trial end
2023-04-01
Status
Withdrawn
Phase
Early phase I
Treatment
Propanolol
Active treatment
Arms:
Propanolol
Other names:
Inderal
Placebo
Arms:
Placebo capsule
Other names:
sugar pill
Primary endpoint
Yale Brown Obsessive-Compulsive Scale
2 weeks
Eligibility criteria
Inclusion Criteria: * Principal Diagnosis of Obsessive-Compulsive Disorder Exclusion Criteria: * History of other serious psychiatric disorder * Current Major Depressive Disorder * Women who are pregnant or nursing * Current use of psychiatric medication * Persons planning to start another treatment during the study period * Any significant medical condition that might increase the risk or participation or use of medications that might negatively interact with propranolol
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'OTHER', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 0, 'type': 'ACTUAL'}}
Updated at
2023-04-18

1 organization

1 product

1 drug

1 indication

Organization
New York State Psychiatric Institute
Product
Propanolol
Indication
Obsessive-Compulsive Disorder
Drug
Varlilumab